August 2026 Research Update

Across studies focused on scans, the main message was that imaging can add detail about inflammation and complications in Behcet's disease, but different tools seem useful in different situations. Expert guidance in eye disease emphasized a small set of imaging tests as most informative, while an exploratory brain MRI approach suggested it may detect artery wall changes not seen on standard vessel imaging, needing follow-up over time. [1] [2]

For Behcet disease uveitis (eye inflammation), an international expert group recommended color retinal photographs, dye-based blood flow imaging of the retina, and a retinal thickness scan as the most relevant tests, with an emphasis on ultra-widefield views. They also described which scan features suggest active inflammation (for example, leakage from retinal vessels or swelling in the macula) and which features suggest later complications (for example, areas with poor blood flow or scarring changes). They judged several other eye imaging methods to have limited utility for this condition. [1]

In Neuro-Behcet syndrome, an exploratory pilot study of 39 adults used a specialized brain MRI technique that looks at the artery wall itself rather than only the space where blood flows. Artery wall involvement was seen in 41% of patients and was mostly in the posterior (back) circulation; wall enhancement was only seen in people scanned during attack periods, and having multiple posterior segments involved correlated with higher disability scores. The authors noted this approach may add information beyond standard lumen-based imaging, but it needs longitudinal validation. [2]

A separate cross-sectional study of 75 people with Behcet's disease (and 40 controls) used visual evoked potentials and a retinal scan to look for silent optic nerve damage. Average test results were similar between Behcet's disease and controls, and only one person met the study definition of subclinical optic neuropathy, suggesting silent optic nerve involvement was uncommon in this group with mild eye involvement. The authors called for larger, longer-term studies, especially in people with neurologic involvement. [3]

For patients with eye involvement, this set of papers mainly clarifies which eye imaging tests experts consider most useful for documenting active inflammation, recovery, and complications, which can help standardize how disease activity is described across clinics. For Neuro-Behcet syndrome, vessel wall MRI is still early-stage research; it may eventually help distinguish attack-related artery inflammation from other changes, but it is not yet validated to predict outcomes or guide decisions. For people with mild eye disease, one study suggests routine testing for silent optic nerve damage may not often find new problems, but uncertainty remains for those with more severe eye or nervous system involvement.

Across biomarker papers, researchers tested whether signals in blood (including different types of RNA and inflammatory proteins) could help identify Behcet's disease or reflect disease activity, but most results are still exploratory and need outside confirmation. One proof-of-concept case report also suggested an ultrasound technique might quantify inflammation around a vein clot and change in parallel with symptoms, but this was shown in only one person. [4] [5] [6] [7]

In a 60-person Behcet's disease versus 60-person healthy control study, several serum RNA markers (NEAT1, MEG3, miR-124, miR-146a) were lower in Behcet's disease, while inflammatory proteins IL-17 and IL-6 were higher. The authors reported that combining multiple RNA markers improved how well the panel separated Behcet's disease from healthy controls, including very high performance in their combined analyses, and they highlighted the need for validation in larger and broader groups. [4]

In another case-control study (50 Behcet's disease and 50 healthy controls), serum circRNA-FUNDC1 and TNF-alpha were higher in Behcet's disease and tended to be higher in active versus inactive disease. The study also explored links with specific symptoms and medications, but many of these links were not statistically secure after correcting for multiple comparisons, meaning they should be viewed as preliminary. Diagnostic cutoffs and high accuracy were reported within this dataset, but the authors emphasized the need for external validation and disease-control comparisons beyond healthy people. [5]

A small single-cell blood study (8 Behcet's disease, 8 healthy controls) mapped immune cell differences and highlighted interferon-related inflammatory pathways, including changes in monocyte subsets. The team proposed a nine-gene diagnostic signature and reported moderate diagnostic performance for one gene (IFI44L), with external datasets supporting increased interferon signaling in certain immune cells. Because of the small sample size and limited clinical detail, these results are best viewed as hypothesis-generating rather than ready for clinical testing. [6]

A single-patient case report followed a man with Behcet's disease and superficial vein thrombosis using an ultrasound microflow method to measure a 'vascularity index' around the clot as a sign of local inflammation. Over 6 months, the vascularity index fell while symptoms improved and the clot regressed, and the blood inflammation marker C-reactive protein also decreased. The authors noted that measurement choices are operator-dependent and that larger studies are needed to confirm repeatability. [7]

These studies provide background on possible future lab and imaging tools that could complement clinical assessment, but they are not yet established tests for routine diagnosis or monitoring. The blood biomarker work mostly compared Behcet's disease to healthy controls, so it remains unclear how well these markers would distinguish Behcet's disease from other inflammatory conditions seen in real clinics. The ultrasound microflow approach is at an even earlier stage because it was shown in one patient; it suggests a way to quantify local vein inflammation, but reliability across different scanners, operators, and patient groups is still uncertain.

This month, the evidence ranged from a larger, non-randomized clinical cohort to small single-center eye data and individual case reports. Overall, the papers suggest that controlling Behcet's disease inflammation can look different depending on which body area is most affected, and benefits may come with trade-offs such as side effects or the need for repeat procedures. [8] [9] [10] [11]

In a retrospective cohort of 355 adults with Behcet's disease affecting the skin and mucous membranes, adding total glucosides of paeony (TGP) to colchicine was linked to fewer returns of oral and genital ulcers in the first two months compared with colchicine alone (for example, oral ulcers at month 2 in 0% versus 100%), while from month 3, when all patients were switched to the combination, neither group had ulcers. The combination group had lower inflammation blood testing (erythrocyte sedimentation rate) at month 2, while another marker (C-reactive protein) was similar between groups. Diarrhea was much more common in the combination group during the first 3 months, and no drug-related low blood counts were reported in either group. [8]

For eye inflammation, a single-center retrospective study of 21 people (28 eyes) with non-infectious uveitis-related macular swelling, only one of whom had Behcet's disease, reported that a dexamethasone implant placed in the eye improved retinal thickness and vision measures most noticeably early on, with the effect decreasing over time in many eyes. Some eyes needed repeat implants, and side effects included higher eye pressure (including three eyes above 30 mmHg controlled with eye drops) and cataracts in three eyes. [9]

Two case reports described treatment approaches for less typical or severe situations, but each reflects one person's experience and may not apply to others. One 42-year-old woman with recurrent inflammation around the heart (pericarditis) had long-lasting remission on anakinra, then developed systemic Behcet's disease after tapering and improved again when full-dose anakinra was restarted. A separate report described a 19-year-old with a very large vulvar ulcer who healed after systemic anti-inflammatory treatment and antibiotics followed by a skin flap procedure and topical ointment, with a later recurrence after stopping prednisone that improved with colchicine and topical steroids. [10] [11]

For patients and caregivers, these papers mainly add context about the range of ways Behcet's-related ulcers and inflammation have been treated in different organs, plus broader evidence on a steroid eye implant from a uveitis study that included only one person with Behcet's disease, rather than establishing a single best approach. The strongest piece of evidence here is still non-randomized and focused on mucocutaneous disease, and the eye and heart-related reports are smaller or single-patient experiences, so it remains uncertain how well the results will match any one person's situation. Safety and monitoring issues also varied by approach (for example, diarrhea in the colchicine plus TGP group and eye-pressure changes after the steroid implant), which is important background for discussions of risks and benefits. [8] [9] [10] [11]

This group of papers points to several ways Behcet's disease can involve blood vessels in the chest, including clots inside the heart, clots traveling to the lungs, and inflammation of lung blood vessels that can look like infection on scans. The evidence includes three single-patient case reports plus one moderate-sized cross-sectional study, so the details may not apply to everyone, and long-term risk remains uncertain. Overall, the reports emphasize that imaging and heart rhythm testing can reveal problems that are not obvious from symptoms alone. [12] [13] [14] [15]

One case report described a 44-year-old man with Behcet's disease who had large blood clots inside the heart, severe coronary artery disease, and blood clots in both lungs, and he improved with non-surgical management that included immunosuppressants, a blood thinner, and heart failure treatments. The authors highlighted echocardiography and using multiple imaging tools to sort out complex heart and lung involvement. Because this is one patient, it cannot show how often this pattern happens or which treatments work best for most people. [12]

Another case report described a 28-year-old woman whose lung spots on CT initially resembled a fungal pneumonia, but infection testing was negative and a specialized lung blood vessel scan later showed vasculitis with tiny clots. Her fever and breathing symptoms improved quickly with corticosteroids and Behcet's-directed immunosuppression, and long-term follow-up imaging showed near-complete clearing. This report underscores that lung blood vessel inflammation in Behcet's disease can mimic infection on early imaging. [13]

A separate case report described a 47-year-old man with vascular Behcet's disease and infective endocarditis who required complex heart surgery and mechanical circulatory support, and then developed extensive mesenteric (intestinal) vein thrombosis leading to bowel necrosis and death. The authors raised concern that severe clotting events can occur in Behcet's disease during situations of high stress and inflammation, particularly when mechanical support devices are used, but this single case cannot prove cause and effect. [14]

In a cross-sectional study of 81 people with clinically inactive Behcet's disease compared with 84 healthy controls, several electrocardiogram (ECG) measures related to the balance of heart electrical signals were higher in the Behcet's group. Longer disease duration was the only independent predictor of one of these ECG measures, while a blood inflammation marker was not an independent predictor in the final analysis. The study did not track actual rhythm problems over time, so it cannot say whether these ECG differences translate into more arrhythmias or symptoms. [15]

For patients and caregivers, this set of studies mainly adds context about the range of possible blood vessel-related complications in Behcet's disease involving the heart and lungs, and how they may appear on tests. The case reports suggest that imaging can help distinguish vessel inflammation and clots from other conditions that can look similar (like infection), but single-patient stories cannot predict risk for any individual. The ECG study suggests that subtle heart electrical differences may be present even when Behcet's disease seems inactive, but it is still unknown whether these differences lead to future rhythm problems without longer follow-up.

Across these reports, Behcet's disease was linked to uncommon organ involvement beyond the better-known mouth, skin, eye, and blood vessel symptoms. Because these are single-patient or two-patient reports, they mainly show what can happen and how it was confirmed, not how often it occurs or what will happen for most people. [16] [17]

Two people with Behcet's disease were diagnosed with autoimmune hepatitis, a type of immune-driven liver inflammation, and the diagnosis was confirmed by liver biopsy. They had high immunoglobulin G (IgG) levels and ongoing high liver enzyme blood tests, and both improved after immunosuppressive treatment, with long-term normalization of liver enzymes reported. [16]

One 20-year-old woman with Behcet's disease developed severe trismus (difficulty opening the mouth) due to inflammation of the chewing muscles, described as masticatory myositis. A whole-body inflammation scan (18F-FDG PET/CT) and magnetic resonance imaging (MRI) showed inflammation in these muscles, and follow-up imaging after colchicine showed lower scan activity alongside clinical improvement. [17]

For patients and caregivers, these papers add background awareness that Behcet's disease can sometimes involve less typical organs, including the liver and specific jaw muscles, and that imaging or biopsy may be used to sort out the cause of unusual symptoms or abnormal blood tests. Because the evidence here comes from a few individuals, it cannot tell how common these problems are, who is at risk, or whether the same response would occur in other people.

Across this group, research connected Behcet's disease and Behcet-like symptoms to changes in genes involved in immune signaling, especially cytokine and NF-kB pathways. The clearest message is not that one gene explains most cases, but that multiple rare gene changes may point toward shared inflammation pathways, with many uncertainties because evidence is early and sometimes based on single patients. [18] [19] [20]

In an exploratory Korean whole-exome sequencing study (20 patients and 100 controls), rare variants in six genes (TTN, FOXO3, OR4C5, GXYLT1, ERN1, SIPA1L3) were reported more often in people with Behcet's disease than in controls. A network analysis expanded this to 48 candidate genes that clustered in interleukin and cytokine signaling pathways, suggesting the genetic signals may converge on immune communication systems. Key limitations included small sample size, a sex imbalance, and no functional lab validation. [18]

Two case reports described Behcet-like illness in people with specific gene mutations affecting NF-kB signaling, a major inflammation control pathway. One report was a 5-year-old girl with TNFAIP3 (A20) haploinsufficiency who had recurrent fevers plus mucocutaneous ulcers and gastrointestinal and eye symptoms; she improved after infliximab when colchicine and steroids had not controlled symptoms. [19]

Another report described an adult woman with psoriasis, lichen sclerosus, non-small-cell lung cancer, and anogenital ulcers in a Behcet-like syndrome linked to a novel NF-kB1 mutation. Her ulcers improved with adalimumab after corticosteroids, antibiotics, and colchicine did not help. Because these are single-patient descriptions, they cannot show how often such mutations occur or predict outcomes for others. [20]

For patients and caregivers, this set of studies mainly adds background about why Behcet's disease can look different from person to person: multiple genes may contribute, and some rare single-gene disorders can closely mimic Behcet's disease, including fevers, ulcers, eye symptoms, and bowel symptoms. These reports do not change routine care on their own, and the genetic signals need confirmation in larger and more diverse groups, plus lab work to show how the gene changes affect the immune system. The case reports suggest that, in selected rare genetic situations, targeting tumor necrosis factor (TNF) was linked to improvement, but single cases cannot establish what will work for most people. [18] [19] [20]

Across two real-world cohort studies, Behcet's disease frequently overlapped with other inflammatory illnesses, and inherited variants linked to periodic fevers appeared across multiple childhood inflammatory diagnoses. The overall pattern is that inflammation conditions can cluster and evolve over time, which may help explain why symptoms and diagnoses can be complex for some people. [21] [22]

In a multicenter cohort of 1591 people with Behcet's disease, 15.3% had at least one additional inflammatory comorbid disease. The most common were axial spondyloarthritis (7.2%), familial Mediterranean fever (2.4%), and hidradenitis suppurativa (2.3%), and inflammatory comorbidity was linked to older age, longer disease duration, and higher use of anti-TNF medicines. [21]

In a single-center pediatric cohort of 270 children carrying a heterozygous MEFV variant (a gene linked to familial Mediterranean fever), diagnoses included familial Mediterranean fever (67%) but also other inflammatory diseases such as IgA vasculitis, PFAPA, inflammatory bowel disease, juvenile idiopathic arthritis, chronic nonbacterial osteomyelitis, and Behcet's disease (1%). Fourteen percent were asymptomatic carriers, and among children first labeled with a different inflammatory condition, 30% later developed familial Mediterranean fever during follow-up. [22]

For patients, these studies support the idea that Behcet's disease may occur alongside other inflammatory problems, and that in some children with certain inherited variants, the clinical picture can change over time. This information is most useful for understanding why symptoms may not fit neatly into one label and why clinicians sometimes track more than one inflammatory condition across the years. What remains uncertain is how much these overlaps reflect shared biology versus referral patterns in specialty centers, and how often specific gene variants meaningfully influence day-to-day disease course in Behcet's disease. [21] [22]

Across these papers, a consistent pattern is that Behcet's disease can be difficult to identify early because symptoms may be varied, develop over time, or look like more common illnesses, which can contribute to diagnosis delays. At the same time, living with Behcet's can affect everyday functioning in concrete ways, including missed work and reduced productivity at work. [23] [24] [25]

In a cross-sectional study of 125 people with Behcet syndrome, work impairment was substantial and was similar to that seen in ankylosing spondylitis, while both groups were more affected than healthy controls. Absenteeism was reported by 42% of participants and presenteeism by 48%, and 62% had moderate or high work instability on a work instability scale. [25]

In that same study, major organ involvement was linked to greater on-the-job productivity loss: eye, blood vessel, and nervous system involvement were each connected with higher odds of presenteeism, and worse quality of life scores tracked strongly with more work instability. Disease activity scores were not consistently linked to absenteeism or presenteeism, suggesting that day-to-day impact may not mirror standard activity measures in a simple way. [25]

A paper focused on diagnostic challenges described how Behcet's may present as prolonged fever with erythema nodosum-like skin lesions, especially in tropical or low-prevalence settings where the disease is considered rare. It noted that fever may occur in blood vessel or nervous system Behcet's and can appear before more classic features, which may delay recognition. [23]

A small Polish case series of eight patients highlighted how heterogeneous Behcet's can be in Caucasian patients, including joint symptoms, skin rashes, headaches, and sometimes serious blood vessel events or neurological problems. The authors noted diagnostic delays and emphasized that care often spans multiple specialties because different organs can be involved. [24]

A single pediatric case report described childhood-onset Behcet's presenting with chronic recurrent mouth ulcers and genital ulcers. While this is only one patient, it adds to the picture that Behcet's can begin in childhood and may start with recurring mucosal ulcers. [26]

For patients and caregivers, this set of studies mainly provides context about why diagnosis can take time and what parts of living with Behcet's are commonly disrupted. The work-focused study suggests that reduced productivity and work instability are common and may be more pronounced when the eyes, blood vessels, or nervous system are involved, while diagnostic papers underline that early symptoms can be non-specific (like fever or certain skin lesions) or differ by person and age. What remains uncertain is how often these patterns apply in other regions and healthcare settings, since some evidence comes from small series or single cases and one larger study captured only a snapshot in time. [25] [23] [24] [26]